Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2008-05-29 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2008-05-29 English
PRIMARY DOCUMENT
Director's Dealing
2008-05-23 English
PRIMARY DOCUMENT
Director's Dealing
2008-05-07 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Q1 2008
2008-05-07 English
8-K REINEMUND
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically details the resignation of a director, Mr. Steven S Reinemund, from the Board of Directors of Johnson & Johnson. This corresponds to an announcement of a change in the company's board of directors. The document does not contain financial data or other report types but focuses on management changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on this event, confirming the classification.
2008-04-24 English
DEFINITIVE ADDITIONAL MATERIALS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, specifically labeled as "Definitive Additional Materials" related to a proxy statement for an annual meeting of shareholders. It discusses voting recommendations and shareholder communications about director elections and executive compensation. This type of document is used to provide additional information to shareholders to solicit votes, fitting the definition of Proxy Solicitation & Information Statement (PSI). The document is not a full annual report, earnings release, or other financial report, but rather additional proxy materials. Therefore, the correct classification is PSI with high confidence.
2008-04-15 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.